首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Comparison of Thyrotropin-Receptor Antibodies Measured by Four Commercially Available Methods with a Bioassay That Uses Fisher Rat Thyroid Cells
【24h】

Comparison of Thyrotropin-Receptor Antibodies Measured by Four Commercially Available Methods with a Bioassay That Uses Fisher Rat Thyroid Cells

机译:通过四种市售方法与使用Fisher大鼠甲状腺细胞的生物测定法测量的促甲状腺素受体抗体的比较

获取原文
           

摘要

Quantification of thyrotropin-receptor antibodies is important in the diagnosis and management of patients with Graves disease (1). Antibodies with stimulating activity (TSI) have traditionally been detected in bioassays that measure their effect on cloned rat thyroid cells (FRTL-5) or on Chinese hamster ovary (CHO) cells transfected with recombinant human thyrotropin-stimulating hormone (TSH) receptor (2)(3). These assays can detect antibodies in up to 95% of untreated hyperthyroid Graves patients, but, with few exceptions (4), they require cell culture facilities and are labor intensive and time consuming.As an alternative to bioassays, several manufacturers have developed competitive immunoassays that measure the inhibition of the binding of labeled TSH by antibodies in patients’ sera. These methods use porcine TSH receptors and claim clinical sensitivities of ~90%. They cannot, however, distinguish whether the autoantibodies have blocking or stimulating capabilities, which can be important in a subset of patients. The more recent LUMItest? TRAK (TRAK) human assay (BRAHMS AG) uses human recombinant TSH receptors and luminescence-labeled bovine TSH. The manufacturer’s literature cites a clinical trial that achieved a diagnostic sensitivity of almost 99% with the research version of the DYNOtest? TRAK human assay (5).We have been performing the TSI bioassay with FRTL-5 cells routinely for more than 15 years. The TSI test volumes have increased steadily over that time, requiring an ever-increasing number of assays each week. In 1998, we added the Kronus? TRAb radioreceptor assay (TRAb) to our test menu to reduce the number of requests for TSI. During the preimplementation evaluation of the Kronus reagents, we found equivalent results in 80 of 89 random patient samples. Of the remaining nine samples, five were positive by TSI and not by TRAb, and four were positive by TRAb and not by TSI.The availability of the BRAHMS reagents as well as …
机译:促甲状腺激素受体抗体的定量对Graves病患者的诊断和治疗很重要(1)。传统上,在生物测定法中检测到具有刺激活性的抗体(TSI),以测定其对克隆的大鼠甲状腺细胞(FRTL-5)或经重组人促甲状腺激素刺激素(TSH)受体转染的中国仓鼠卵巢(CHO)细胞的作用(2) )(3)。这些检测方法可以检测高达95%的未经治疗的甲状腺功能亢进Graves患者的抗体,但除少数例外(4)之外,它们需要细胞培养设施且劳动强度大且耗时。作为生物检测的替代方法,一些制造商开发了竞争性免疫检测可以测量患者血清中抗体对标记的TSH结合的抑制作用。这些方法使用猪的TSH受体,临床敏感性约为90%。但是,它们无法区分自身抗体是否具有阻断或刺激能力,这在部分患者中可能很重要。最近的LUMItest? TRAK(TRAK)人类测定法(BRAHMS AG)使用人类重组TSH受体和发光标记的牛TSH。制造商的文献援引了一项临床试验,使用DYNOtest?的研究版本,诊断敏感性达到了近99%。 TRAK人​​体检测(5)。我们已经对FRTL-5细胞进行了TSI生物检测超过15年。在此期间,TSI测试量稳步增加,每周需要不断增加的测定数量。 1998年,我们加入了克朗努斯?将TRAb放射受体测定(TRAb)移至我们的测试菜单,以减少对TSI的请求数量。在Kronus试剂的实施前评估期间,我们在89个随机患者样本中的80个中发现了相同的结果。在其余的9个样本中,有5个被TSI而不是TRAb呈阳性,并且四个被TRAb而不是TSI呈阳性。BRAHMS试剂以及…的可用性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号